Merck KGaA has acquired 100 % of the share capital of Beijing Skywing Technology Co., Ltd., a leading supplier of cell-culture media products, related technical services and bioreactors for the Chinese biopharmaceutical industry.
The company is headquartered in the Changping district of Beijing and currently employs 80 people. The purchase price was CYN 120 million (approx. EUR 14 million).
The Chinese biopharmaceutical market is predicted to grow by 20 % over the next years, primarily driven by the local vaccine and antibody industries. Merck plan to utilize this access to the Chinese biopharmaceutical market to leverage Merck Millipore consumables sales like chromatography media, filtration devices and disposable bioreactor solutions.